Methods and compositions for use in the treatment of hyperlipidemia
OwnerYadong Huang, Robert W. Mahley +1inventors
InventorsYadong Huang, Robert W. Mahley, John M. Taylor
Life of this patent
Estimating the term…
Abstract
Methods of treating a host suffering from hyperlipidemia resulting from elevated levels of at least one of VLDL and triglycerides are provided. In the subject methods, an effective amount of agent that reduces the level of active apoE, e.g. apoE inhibitor or apoE expression inhibitor, is administered to the host. The subject methods find particular use in the treatment of hosts suffering from Type IV or Type IIb hyperlipidemia. Also provided are non-human transgenic animal models for hyperlipidemia, as well as methods for making and using the subject animal models, e.g. in therapeutic agent screening applications.
Claims35
A method for reducing the plasma level of at least one of VLDL and triglycerides in a host, said method comprising:
- administering to said host an effective amount of an agent which at least reduces the amount of plasma active apoE in said host.
A method of treating a host suffering from a disease condition associated with elevated plasma levels of at least one of VLDL and triglycerides, said method comprising:
- administering to said host an effective amount of an agent that at least reduces the plasma amount of active apoE in said host.
A non-human transgenic animal model of hyperlipidemia, wherein said non-human animal model over-expresses human apo E in a manner sufficient to have a high apoE plasma level, with the proviso that when said non-human transgenic animal model is a lagomorph, said apoE is apoE3.
A rodent transgenic animal model of hypertriglyceridemia that over-expresses human apolipoprotein E and does not express endogenous apolipoprotein E.
A lagomorph transgenic animal model of hyperlipidemia that over-expresses human apolipoprotein E3.
Dependencies are inferred from the claim text.